Behavioral recovery in MPTP-treated monkeys: Neurochemical mechanisms studied by intrastriatal microdialysis

Journal of Neuroscience

Volumn 28, Issue 38, 2008, Pages 9575-9584

  Boulet, Sabrina ^a,b,c   Mounayar, Stéphanie ^a,d   Poupard, Annie ^a,b,c   Bertrand, Anne ^a,b,c   Jan, Caroline ^a,d   Pessiglione, Mathias ^a,d   Hirsch, Etienne C ^a,d   Feuerstein, Claude ^a,b,c   François, Chantal ^a,d   Féger, Jean ^a,d   Savasta, Marc ^a,b,c,f   Tremblay, Léon ^e  

^a INSERM   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIV GRENOBLE ALPES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ LYON 1   (France)

^f GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

Microdialysis; MPTP; Parkinson's disease; Primate; Recovery; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; GLUTAMIC ACID; HOMOVANILLIC ACID; NEUROTRANSMITTER; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HISTOPATHOLOGY; LIMBIC CORTEX; MALE; MICRODIALYSIS; MONKEY; MOTOR PERFORMANCE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SENSORIMOTOR CORTEX;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; CERCOPITHECUS AETHIOPS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOWN-REGULATION; EXTRACELLULAR FLUID; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MICRODIALYSIS; MOVEMENT; NEUROTRANSMITTER AGENTS; PARKINSONIAN DISORDERS; RECOVERY OF FUNCTION; SEROTONIN; UP-REGULATION;

EID: 58149333196     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3465-08.2008     Document Type: Article

References (60)

1. Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson's disease. In: Movement Disorders (Marsden CD, Fahn S, eds), pp 166-230. London: Springer/Butterworth.
2. Benloucif S, Galloway MP (1991) Facilitation of dopamine release in-vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200:1-8.
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
4. Bezard E, Boraud T, Bioulac B, Gross CE (1997) Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 81:399-404.
5. Bezard E, Jaber M, Gonon F, Boireau A, Bloch B, Gross CE (2000) Adaptative changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci 12:2892-2900.
6. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21:6853-6861.
7. Blanchard V, Anglade P, Dziewczapolski G, Savasta M, Agid Y, Raisman-Vozari R (1996) Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res 709:319-325.
8. Bradberry CW (2000) Applications of microdialysis methodology in nonhuman primates: Practice and rationale. Crit Rev Neurobiol 14:143-163.
9. Bruet N, Windels F, Carcenac C, Feuerstein C, Bertrand A, Poupard A, Savasta M (2003) Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats. J Neuropathol Exp Neurol 62:1228-1240.
10. Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bédard PJ, Di Paolo T (2003) Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonian with levodopa-induced motor complications. Mov Disord 18:241-253.
11. Davis MD, Heffner TG, Cooke LW (1997) Dopamine agonist-induced inhibition of neurotransmitter release from the awake squirrel monkey putamen as measured by microdialysis. J Neurochem 68:659-666.
12. de Lange EC, de Boer AG, Breimer DD (2000) Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45:125-148.
13. Dentresangle C, Le Cavorsin M, Savasta M, Leviel V (2001) Increased basal extracellular dopamine levels and normal evoked dopamine overflow at an early stage of striatal deafferentation. Brain Res 893:178-185.
14. Elsworth JD, Deutch AY, Redmond DE Jr, Sladek JR Jr, Roth RH (1987) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Res 415:293-299.
15. Elsworth JD, Deutch AY, Redmond DE Jr, Taylor JR, Sladek JR Jr, Roth RH (1989) Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated primates: biochemical changes in striatal regions. Neuroscience 33:323-331.
16. Elsworth JD, Taylor JR, Sladek JR Jr, Collier TJ, Redmond DE Jr, Roth RH (2000) Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 95:399-408.
17. François C, Yelnik J, Tandé D, Agid Y, Hirsch EC (1999) Dopaminergic cell group A8 in the monkey: anatomical organization and projections to the striatum. J Comp Neurol 414:334-347.
18. Fuxe K, Agnati LF (1991) Two principal modes of electrochemical communication in the brain: volume versus wiring transmission. In: Volume transmission in the brain: novel mechanisms for neural transmission (Fuxe K, Agnati LF, eds), pp 1-9. New York: Raven.
19. Gaspar P, Febvret A, Colombo J (1993) Serotoninergic sprouting in primate MPTP-induced hemiparkinsonism. Exp Brain Res 96:100-106.
20. Georgieva J, Luthman J, Mohringe B, Magnusson O (1993) Tissue and microdialysate changes after repeated and permanent probe implantation in the striatum of freely moving rats. Brain Res Bull 31:463-470.
21. Hefti F, Melamed E, Wurtman RJ (1980) Partial lesions of the dopaminergic nigro-striatal system in rat brain: biochemical characterization. Brain Res 195:123-137.
22. Hornykiewicz O (1975) Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 3:13-21.
23. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease. Neurology 51:S2-S9.
24. Hornykiewicz O (2001) Chemical neuroanatomy of the basal ganglia-normal and in Parkinson's disease. J Chem Neuroanat 22:3-12.
25. Jan C, François C, Tandé D, Yelnik J, Tremblay L, Agid Y, Hirsch E (2000) Dopaminergic innervation of the pallidum in the normal state, MPTP-treated monkeys and Parkinsonian patients. Eur J Neurosci 12:4525-4535.
26. Jan C, Pessiglione M, Tremblay L, Tandé D, Hirsch EC, François C (2003) Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys. Eur J Neurosci 18:2082-2086.
27. Khan SH, Shuaib A (2001) The technique of intracerebral microdialysis. Methods 23:3-9.
28. Kish S, Rajput A, Gilbert J, Rozdilsky B, Chang LJ, Shannak K, Hornykiewicz O (1987) GABA-dopamine relationship in Parkinson's disease striatum. Adv Neurol 45:75-77.
29. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318:876-880.
30. Kolachana BS, Saunders RC, Weinberger DR (1994) An improved methodology for routine in vivo microdialysis in non-human primates. J Neurosci Methods 55:1-6.
31. Kornhuber J, Kornhuber ME (1986) Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci 39:699-674.
32. Lindefors N (1993) Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review. Prog Neuropsychopharmacol Biol Psychiatry 17:887-903.
33. Lindefors N, Ungerstedt U (1990) Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett 115:248-252.
34. McCallum SE, Parameswaran N, Perez XA, Bao S, McIntosh JM, Grady SR, Quik M (2006) Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates. J Neurochem 96:960-972.
35. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88:1-16.
36. Mounayar S, Boulet S, Tandé D, Jan C, Pessiglione M, Hirsch EC, Féger J, Savasta M, François C, Tremblay L (2007) A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130:2898-2914.
37. Ohara K, Kondo N, Ohara K (1998) Changes of monoamines in postmortem brains from patients with diffuse Lewy body disease. Prog Neuropsychopharmacol Biol Psychiatry 22:311-317.
38. Pérez-Otaño I, Herrero MT, Oset C, De Ceballos ML, Luquin MR, Obeso JA, Del Río J (1991) Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res 567:127-132.
39. Petzinger GM, Fisher B, Hogg E, Abernathy A, Arevalo P, Nixon K, Jakowec MW (2006) Behavioural motor recovery in the MPTP lesioned squirrel monkey: changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. J Neurosci Res 83:332-347.
40. Pifl C, Schingnitz G, Hornykiewicz O (1991) Effect of MPTP on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44:591-605.
41. Plenz D (2003) When inhibition goes incognito: feedback interaction between spiny projection neurons in striatal function. TRENDS Neurosci 26:436-443.
42. Raju DV, Ahern TH, Shah DJ, Wright TM, Standaert DG, Hall RA, Smith Y (2008) Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism. Eur J Neurosci 27:1647-1658.
43. Robinson S, Freeman P, Moore C, Touchon JC, Krentz L, Meshul CK (2003) Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp Neurol 180:74-87.
44. Robinson TE, Whishaw IQ (1988) Normalization of extracellular dopamine in the striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450:209-224.
45. Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD (1989) Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett 101:305-310.
46. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328.
47. Schneider JS (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 534:25-36.
48. Schneider JS, Kovelowski CJ 2nd (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519:122-128.
49. Schneider JS, Rothblat DS (1991) Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats. Neuroscience 44:421-429.
50. Schneider JS, Rothblat DS, DiStefano L (1994) Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism. Brain Res 643:86-91.
51. Schwarting RK, Huston JP (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49:215-266.
52. Skirboll S, Wang J, Mefford I, Hsiao J, Bankiewicz KS (1990) In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp Neurol 110:187-193.
53. Song DD, Haber SN (2000) Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 20:5102-5114.
54. Tossman U, Ungerstedt U (1986) Microdialysis in the study of extracellular levels of amino acids in the rat brain. Acta Physiol Scand 128:9-14.
55. Wang J, Skirboll S, Aigner TG, Saunders RC, Hsiao J, Bankiewicz KS (1990) Methodology of microdialysis of neostriatum in hemiparkinsonian nonhuman primates. Exp Neurol 110:181-186.
56. Yadid G, Pacak K, Kopin IJ, Goldstein DS (1994) Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Ther 270:1158-1165.
57. Yamazoe I, Takeuchi Y, Matsushita H, Kawano H, Sawada T (2001) Serotonergic heterotypic sprouting in the unilaterally dopamine-depleted mouse neostriatum. Dev Neurosci 23:78-83.
58. Zhou FC, Bledsoe S, Murphy J (1991) Serotoninergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556:108-116.
59. Zigmond MJ (1997) Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 4:247-253.
60. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-296.